Pharmacokinetics, tissue distribution, and plasma protein binding study of platinum originating from dicycloplatin, a novel antitumor supramolecule, in rats and dogs by ICP-MS

Biological Trace Element Research

Volumn 148, Issue 2, 2012, Pages 203-208

  Zhao, Di ^a   Zhang, Yongjie ^a   Xu, Chunxiang ^b   Dong, Can ^b   Lin, Hui ^b   Zhang, Lingli ^a   Li, Cuiyun ^a   Ren, Shuangxia ^a   Wang, Xin ^a   Yang, Shuoye ^a   Han, Deen ^a   Chen, Xijing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Product Quality Test and Inspect Institute   (China)

Author keywords

Antitumor supramolecule; Dicycloplatin; ICP MS; Pharmacokinetics; Tissue distribution

Indexed keywords

CARBOPLATIN; DICYCLOPLATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; MALE; MASS SPECTROMETRY; NONHUMAN; PROTEIN BINDING; RAT; SINGLE DRUG DOSE; SUPRAMOLECULAR CHEMISTRY; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; ORGANOPLATINUM COMPOUNDS; PLATINUM; PROSTATE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; TESTIS; TIME FACTORS; TISSUE DISTRIBUTION;

CANIS FAMILIARIS; RATTUS;

EID: 84864699056     PISSN: 01634984     EISSN: 15590720     Source Type: Journal    
DOI: 10.1007/s12011-012-9364-2     Document Type: Article

References (31)

1. Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (2009) Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 219:177-186
2. Ji S, Chueh HW, Kim JY, Lim SJ, Cho EJ, Lee SH, Yoo KH, Sung KW, Koo HH (2011) Responses and adverse effects of carboplatinbased chemotherapy for pediatric intracranial germ cell tumors. Korean J Pediatr 54:128-132
3. Alberts DS, Dorr RT (1998) New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. Oncologist 3:15-34 (Pubitemid 28106719)
4. Goto Y, Sekine I, Tanioka M, Shibata T, Tanai C, Asahina H, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Kikkawa H, Ohki E, Tamura T (2011) Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced nonsmall cell lung cancer. Invest New Drugs. doi:10.1007/s10637- 011-9715-4
5. Yang X, Jin X, Song Q, Tang K, Yang Z, Zhang X, Tang Y (2010) Structural studies of dicycloplatin, an antitumor supramolecule. Sci China Chem 53:1346-1351
6. Peng J, Wu H, Guan Z (2009) Chemotherapy-naive patients with advanced non-small-cell lung cancer-single institution experience. Chin J Clin Oncol 3:711-714
7. Wang C, Yan R (2005) Assay of the lung cancer cell apoptosis induced by dicycloplatin. J Practical Oncol 19:21-22
8. Yan D, Tu L, Peng X, Li W, Shen Z (2007) In vitro and in vivo antitumour activity of dicycloplatin, a new active platinum complex. Chin JMAP 24:352-356
9. Cao B, Chen X, Gu X, Wang G (2003) Pharmacokinetics of 0325k1-1 in dogs. J China Pharm Univ 34:369-371
10. Chen X, Liu X, Zhang G, Gu X, Meng H, Xin F, Li N, Wang G, Zhu J (2000) The pharmacokinetics of 0325k1-1 in rats. J China Pharm Univ 31:56-60
11. Villarino N, Cox S, Yarbrough J, Martín-Jiménez T (2010) Determination of carboplatin in canine plasma by high-performance liquid chromatography. Biomed Chromatogr 24:908-913
12. Warren K, Gervais A, Aikin A, Egorin M, Balis FM (2004) Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother Pharmacol 54:206-212 (Pubitemid 39141736)
13. Delord JP, Umlil A, Guimbaud R, Grégoire N, Lafont T, Canal P, Bugat R, Chatelut E (2003) Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol 51:127-131 (Pubitemid 36259472)
14. Sova P, Mistr A, Kroutil A, Semerád M, Chlubnová H, Hrusková V, Chládková J, Chládek J (2011) A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum (IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine) amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis (acetato) amminedichloro(cyclohexylamine)platinum(IV). Cancer Chemother Pharmacol 67:1247-1256
15. Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM (2005) Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res 11:1669-1674 (Pubitemid 40315252)
16. da Costa AC, Jr VMA, Luna AS, de Campos RC (2010) Determination of platinum originated from antitumoral drugs in human urine by atomic absorption spectrometric methods. Talanta 82:1647-1653
17. Stürup S (2004) The use of ICPMS for stable isotope tracer studies in humans: a review. Anal Bioanal Chem 378:273-282 (Pubitemid 40890235)
18. Morrison JG, White P, McDougall S, Firth JW, Woolfrey SG, Graham MA, Greenslade D (2000) Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 24:1-10
19. Breda M, Maffini M, Mangia A, Mucchino C, Musci M (2008) Development and validation of an inductively coupled plasma mass spectrometry method with optimized microwave-assisted sample digestion for the determination of platinum at ultratrace levels in plasma and ultrafiltrate plasma. J Pharm Biomed Anal 48:435-439
20. Liu QF, Li X, Su Q, Luo GA, Wang YM, Liu WP (2009) Investigation on pharmacokinetics, tissue distribution and excretion of a novel anticancer platinum compound by inductively coupled plasma mass spectrometry after intravenous administration to rats. Arch Pharm Res 32:1621-1628
21. Brouwers EE, Tibben MM, Rosing H, Hillebrand MJ, Joerger M, Schellens JH, Beijnen JH (2006) Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J Mass Spectrom 41:1186-1194 (Pubitemid 44454172)
22. Clerico A, Cappelli C, Ragni G, Caroli S, De Ioris MA, Sordi A, Petrucci F, Bocca B, Alimonti A (2006) Evaluation of carboplatin pharmacokinetics in pediatric oncology by means of inductively coupled plasma mass spectrometry. Ann Ist super Sanita 42:461-468
23. Spezia S, Bocca B, Forte G, Gatti A, Mincione G, Ronchi A, Bavazzano P, Alimonti A, Minoia C (2005) Comparison of inductively coupled plasma mass spectrometry techniques in the determination of platinum in urine: quadrupole vs. sector field. Rapid Commun Mass Spectrom 19:1551-1556 (Pubitemid 40801999)
24. Ghezzi A, Aceto M, Cassino C, Gabano E, Osella D (2004) Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS). J Inorq Biochem 98:73-78 (Pubitemid 37495012)
25. Siddik ZH, Newell DR, Boxall FE, Harrap KR (1987) The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36:1925-1932 (Pubitemid 17100213)
26. Newell DR, Siddik ZH, Gumbrell LA, Boxall FE, Gore ME, Smith IE, Calvert AH (1987) Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol 23:1399-1405 (Pubitemid 18006730)
27. Qin Z, Caruso JA, Lai B, Matusch A, Becker JS (2011) Trace metal imaging with high spatial resolution: applications in biomedicine. Metallomics 3:28-37
28. Su L, Mruk DD, Lee WM, Cheng CY (2011) Drug transporters and blood-testis barrier function. J Endocrinol 209:337-351
29. Liebner S, Czupalla CJ, Wolburg H (2011) Current concepts of blood-brain barrier development. Int J Dev Biol 55:467-476
30. Sterbis JR, Rice KR, Javitt MC, Schenkman NS, Brassell SA (2010) Fusion imaging: a novel staging modality in testis cancer. J Cancer 1:223-229
31. Schwaab T, Pili R (2011) Provenge: combating prostate cancer with a vengeance? Expert Rev Vaccines 10:1113-1114